Loading the company…
Loading the company…
Families: Bone graft & orthobiologics, Lumbar fusion.
All companies · Product and company coverage
In 2025, Biocomposites reported engagement with 1,688 surgeons and other clinicians in the states MedaRep covers, worth $176K in consulting, speaking, meals and travel for its device products, the most in Florida ($45K to 194). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Florida ($45K, 194 engaged), Virginia ($17K, 44 engaged), California ($13K, 59 engaged), Pennsylvania ($12K, 126 engaged), New York ($12K, 153 engaged).
In the last ten years FDA made 4 decisions for Biocomposites (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 2 procedure families, the most in 2025 (2). The latest was on 2026-02-17.
| Family | Decisions on record |
|---|---|
| Bone graft & orthobiologics | 11 |
| Lumbar fusion | 11 |
| STIMULAN KIT, STIMULAN RAPID CURE |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Biocomposites.